Psilocybin brain changes track setting, backing session design

Clinical takeaway: Patients weighing psilocybin can be told that session conditions appear to shape the brain response, not just the dose. 

Psychedelic session design is elaborate and strikingly uniform across programs, built on consensus experience rather than a well-understood mechanism. Brain imaging now shows what happens during these sessions, in the process offering a clearer scientific rationale for the tightly structured protocols used in psychedelic trials. 

With two positive phase 3 trials of psilocybin now reported in treatment-resistant depression and licensed programs running in Oregon and Colorado, more generalists will field questions about what a supervised session involves. Treatment protocols are fairly consistent but thinly explained. 

Under psilocybin, brain activity separated out cleanly by what participants were doing. A classifier reading each person's moment-to-moment brain trajectory could tell rest from meditation from music from movie watching. The separation was graded rather than uniform: those reporting more intense experiences showed tighter, more distinct patterns. How cleanly the classifier could separate conditions became a measure in itself, and that measure tracked the intensity of the acute experience and, more modestly, next-day change on a questionnaire covering connection to self, others, and nature, along with patience and inner peace. 

Functional modularity, the measure most psychedelic imaging relies on, tells a different story. It captures how much the brain stays sorted into distinct, separate networks, averaged across a whole scan. Modularity dropped sharply under psilocybin in every condition, confirming a robust drug effect, but it predicted nothing about which participants had an intense session or changed the most. What predicted individual response was the moment-to-moment dynamics. 

By contrast, the eight-week preparation course made no measurable difference. Of the participants, about half completed mindfulness-based cognitive therapy before dosing, attending at least six of eight sessions and averaging 85 minutes of independent practice a week; the other group received no intervention. Neither acute subjective effects nor any connectivity measure separated the groups, and the investigators pooled them for the main analyses. 

The open-label study scanned 62 healthy adults at baseline and again after a single 19 mg oral dose. All were psychedelic-naive and screened to exclude psychiatric history. Each session paired functional MRI with 64-channel EEG, beginning about 80 minutes after dosing. There was no placebo arm. Assignment to the meditation course followed class availability rather than randomization, and that comparison was secondary. 

The authors suggest a potential use for brain imaging during a session, to gauge how strongly someone is responding. But the technical requirements are high: an fMRI scanner, a trained machine learning model, and trained session staff. All of that to predict what can more simply be answered via a next-day questionnaire. The real-world case remains questionable for now. 

"We uncovered hidden order within that disruption. Under psilocybin, brain networks that help us process our inner world and the world around us became less distinct, but reorganised into patterns that reflected what people were experiencing," said Devon Stoliker, lead author, of the Turner Institute for Brain and Mental Health at Monash University. "This was strongest in people who had more positive psychedelic experiences and felt less separate from the world around them." 

Source: Stoliker D, et al. (2026 Aug 19) Nature. Psychedelics align brain activity with context